



GRANTING OF US PATENT FOR DERMAPORTATION TECHNOLOGY

OBJ Limited (ASX:OBJ) today announced that it has received the Dermaportation Patent issued by the US Patent office, following the allowance of claims announced on 23 August 2011.

The granting of the patent enhances the potential commercial value of the Company's powered Dermaportation technology as it allows the Company to offer various market licensing options to potential partners in key market sectors.

The Company has identified several commercial opportunities for Dermaportation and has introduced the technology to potential partners.

About OBJ:

OBJ is the leading developer of magnetic micro-array drug delivery and product enhancement technologies.

OBJ partners leading companies in the design and development of next generation products using physical science rather than chemistry to provide new levels of product performance without the cost of reformulation or new ingredient approvals.

OBJ provides partnering and design expertise in:

- Transdermal Drug Delivery
- Cosmetic and Therapeutic Skincare
- Oral Health, Haircare and Deo-actives
- High Penetration Surface Care and Hygiene

OBJ offers a portfolio of proprietary technologies and supports partners by providing IP protected market exclusivity, expertise in magnetic array design, feasibility and efficacy and claims testing, engineering and production.

About OBJ's Technologies

OBJ has developed a platform of physical enhancement technologies based on low-cost magnetic micro-arrays that influence the movement and penetration of drugs, active ingredients and formulations at the molecular level.

Complex 3-D array and moving magnetic fields have the ability to repulse certain molecules to enhance diffusion and to alter the permeability of certain biological and non-biological targets.

OBJ is the first company to develop low-cost micro-array film technology that utilises diamagnetic repulsion, induced permeation and energy redirection to offer a new way of managing the speed, depth of penetration and delivery of active ingredients in a wide range of pharmaceutical and consumer products.

- End -

For more information:

Mr Glyn Denison Director

P +618 9443 3011

E gdenison@obj.com.au

W www.obj.com.au

For personal use only